Synonyms: Addyi® | BIMT-17 | Girosa® (proposed trade name)
flibanserin is an approved drug (FDA (2015))
Compound class:
Synthetic organic
Comment: Flibanserin is reported as a serotonin 5-HT1A agonist and 5-HT2A antagonist [2]. The compound was originally investigated as a antidepressant [3-4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Flibanserin was approved for use as a non-hormonal treatment for pre-menopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD) in August 2015. Flibanserin is approved with a 'Boxed Warning' to highlight the risks of severe hypotension and syncope in patients who drink alcohol whilst taking this drug. Click here to link to ClinicalTrials.gov's full list of Phase 3 flibanserin trials. |
Mechanism Of Action and Pharmacodynamic Effects |
Flibanserin targets 5-HT1A and 5-HT2A receptors in selective brain areas [1] and helps to restore the balance between inhibitory serotonin and and excitatory dopamine/noradrenaline effects believed to be requisite for a healthy sexual response. |